×

ENTER REPORT NAME TO SEARCH

Global EGFR Inhibitors for Lung Cancer Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2030

Report ID: IBI1622130 | Category: Pharma & Healthcare | Pages: 130 | Format: PDF | Published Date: August 18,2023

Request Sample      Enquiry before buying    Ask For Discount   

Table of Contents

1 Market Overview
    1.1 EGFR Inhibitors for Lung Cancer Introduction
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global EGFR Inhibitors for Lung Cancer Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Geftinib
        1.3.3 Afatinib
        1.3.4 Osimertinib
        1.3.5 Other
    1.4 Market Analysis by Application
        1.4.1 Overview: Global EGFR Inhibitors for Lung Cancer Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Medical Care
        1.4.3 Experiment
        1.4.4 Others
    1.5 Global EGFR Inhibitors for Lung Cancer Market Size & Forecast
        1.5.1 Global EGFR Inhibitors for Lung Cancer Consumption Value (2019 & 2022 & 2030)
        1.5.2 Global EGFR Inhibitors for Lung Cancer Sales Quantity (2019-2030)
        1.5.3 Global EGFR Inhibitors for Lung Cancer Average Price (2019-2030) 
2 Manufacturers Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer EGFR Inhibitors for Lung Cancer Product and Services
        2.1.4 Pfizer EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.1.5 Pfizer Recent Developments/Updates
    2.2 AstraZeneca
        2.2.1 AstraZeneca Details
        2.2.2 AstraZeneca Major Business
        2.2.3 AstraZeneca EGFR Inhibitors for Lung Cancer Product and Services
        2.2.4 AstraZeneca EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.2.5 AstraZeneca Recent Developments/Updates
    2.3 Genentech (Roche Group)
        2.3.1 Genentech (Roche Group) Details
        2.3.2 Genentech (Roche Group) Major Business
        2.3.3 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product and Services
        2.3.4 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.3.5 Genentech (Roche Group) Recent Developments/Updates
    2.4 Beta Pharma
        2.4.1 Beta Pharma Details
        2.4.2 Beta Pharma Major Business
        2.4.3 Beta Pharma EGFR Inhibitors for Lung Cancer Product and Services
        2.4.4 Beta Pharma EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.4.5 Beta Pharma Recent Developments/Updates
    2.5 Mylan
        2.5.1 Mylan Details
        2.5.2 Mylan Major Business
        2.5.3 Mylan EGFR Inhibitors for Lung Cancer Product and Services
        2.5.4 Mylan EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.5.5 Mylan Recent Developments/Updates
    2.6 Boehringer Ingelheim
        2.6.1 Boehringer Ingelheim Details
        2.6.2 Boehringer Ingelheim Major Business
        2.6.3 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product and Services
        2.6.4 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.6.5 Boehringer Ingelheim Recent Developments/Updates
    2.7 Teva Pharmaceuticals
        2.7.1 Teva Pharmaceuticals Details
        2.7.2 Teva Pharmaceuticals Major Business
        2.7.3 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services
        2.7.4 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.7.5 Teva Pharmaceuticals Recent Developments/Updates
    2.8 Qilu Pharmaceutical
        2.8.1 Qilu Pharmaceutical Details
        2.8.2 Qilu Pharmaceutical Major Business
        2.8.3 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product and Services
        2.8.4 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.8.5 Qilu Pharmaceutical Recent Developments/Updates
    2.9 Betta Pharmaceuticals
        2.9.1 Betta Pharmaceuticals Details
        2.9.2 Betta Pharmaceuticals Major Business
        2.9.3 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services
        2.9.4 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.9.5 Betta Pharmaceuticals Recent Developments/Updates
    2.10 Haosen Pharmaceutical
        2.10.1 Haosen Pharmaceutical Details
        2.10.2 Haosen Pharmaceutical Major Business
        2.10.3 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product and Services
        2.10.4 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.10.5 Haosen Pharmaceutical Recent Developments/Updates
    2.11 ARIAD Pharmaceuticals
        2.11.1 ARIAD Pharmaceuticals Details
        2.11.2 ARIAD Pharmaceuticals Major Business
        2.11.3 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services
        2.11.4 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.11.5 ARIAD Pharmaceuticals Recent Developments/Updates
    2.12 HUTCHMED
        2.12.1 HUTCHMED Details
        2.12.2 HUTCHMED Major Business
        2.12.3 HUTCHMED EGFR Inhibitors for Lung Cancer Product and Services
        2.12.4 HUTCHMED EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.12.5 HUTCHMED Recent Developments/Updates
    2.13 Shanghai Ellis
        2.13.1 Shanghai Ellis Details
        2.13.2 Shanghai Ellis Major Business
        2.13.3 Shanghai Ellis EGFR Inhibitors for Lung Cancer Product and Services
        2.13.4 Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.13.5 Shanghai Ellis Recent Developments/Updates
    2.14 Genvio Pharma
        2.14.1 Genvio Pharma Details
        2.14.2 Genvio Pharma Major Business
        2.14.3 Genvio Pharma EGFR Inhibitors for Lung Cancer Product and Services
        2.14.4 Genvio Pharma EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.14.5 Genvio Pharma Recent Developments/Updates
    2.15 Everest Pharmaceuticals
        2.15.1 Everest Pharmaceuticals Details
        2.15.2 Everest Pharmaceuticals Major Business
        2.15.3 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services
        2.15.4 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.15.5 Everest Pharmaceuticals Recent Developments/Updates
    2.16 Incepta Pharmaceuticals
        2.16.1 Incepta Pharmaceuticals Details
        2.16.2 Incepta Pharmaceuticals Major Business
        2.16.3 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product and Services
        2.16.4 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.16.5 Incepta Pharmaceuticals Recent Developments/Updates
    2.17 Jiangsu Hengrui Medicine
        2.17.1 Jiangsu Hengrui Medicine Details
        2.17.2 Jiangsu Hengrui Medicine Major Business
        2.17.3 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product and Services
        2.17.4 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2022)
        2.17.5 Jiangsu Hengrui Medicine Recent Developments/Updates
3 Competitive Environment: EGFR Inhibitors for Lung Cancer by Manufacturer
    3.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Manufacturer (2019-2022)
    3.2 Global EGFR Inhibitors for Lung Cancer Revenue by Manufacturer (2019-2022)
    3.3 Global EGFR Inhibitors for Lung Cancer Average Price by Manufacturer (2019-2022)
    3.4 Market Share Analysis (2021)
        3.4.1 Producer Shipments of EGFR Inhibitors for Lung Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2021
        3.4.2 Top 3 EGFR Inhibitors for Lung Cancer Manufacturer Market Share in 2021
        3.4.2 Top 6 EGFR Inhibitors for Lung Cancer Manufacturer Market Share in 2021
    3.5 EGFR Inhibitors for Lung Cancer Market: Overall Company Footprint Analysis
        3.5.1 EGFR Inhibitors for Lung Cancer Market: Region Footprint
        3.5.2 EGFR Inhibitors for Lung Cancer Market: Company Product Type Footprint
        3.5.3 EGFR Inhibitors for Lung Cancer Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
    4.1 Global EGFR Inhibitors for Lung Cancer Market Size by Region
        4.1.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Region (2019-2030)
        4.1.2 Global EGFR Inhibitors for Lung Cancer Consumption Value by Region (2019-2030)
        4.1.3 Global EGFR Inhibitors for Lung Cancer Average Price by Region (2019-2030)
    4.2 North America EGFR Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.3 Europe EGFR Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.4 Asia-Pacific EGFR Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.5 South America EGFR Inhibitors for Lung Cancer Consumption Value (2019-2030)
    4.6 Middle East and Africa EGFR Inhibitors for Lung Cancer Consumption Value (2019-2030)
5 Market Segment by Type
    5.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    5.2 Global EGFR Inhibitors for Lung Cancer Consumption Value by Type (2019-2030)
    5.3 Global EGFR Inhibitors for Lung Cancer Average Price by Type (2019-2030)
6 Market Segment by Application
    6.1 Global EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    6.2 Global EGFR Inhibitors for Lung Cancer Consumption Value by Application (2019-2030)
    6.3 Global EGFR Inhibitors for Lung Cancer Average Price by Application (2019-2030)
7 North America
    7.1 North America EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    7.2 North America EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    7.3 North America EGFR Inhibitors for Lung Cancer Market Size by Country
        7.3.1 North America EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        7.3.2 North America EGFR Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)
8 Europe
    8.1 Europe EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    8.2 Europe EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    8.3 Europe EGFR Inhibitors for Lung Cancer Market Size by Country
        8.3.1 Europe EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        8.3.2 Europe EGFR Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)
9 Asia-Pacific
    9.1 Asia-Pacific EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific EGFR Inhibitors for Lung Cancer Market Size by Region
        9.3.1 Asia-Pacific EGFR Inhibitors for Lung Cancer Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific EGFR Inhibitors for Lung Cancer Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)
10 South America
    10.1 South America EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    10.2 South America EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    10.3 South America EGFR Inhibitors for Lung Cancer Market Size by Country
        10.3.1 South America EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        10.3.2 South America EGFR Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)
11 Middle East & Africa
    11.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa EGFR Inhibitors for Lung Cancer Market Size by Country
        11.3.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)
12 Market Dynamics
    12.1 EGFR Inhibitors for Lung Cancer Market Drivers
    12.2 EGFR Inhibitors for Lung Cancer Market Restraints
    12.3 EGFR Inhibitors for Lung Cancer Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
    13.1 Raw Material of EGFR Inhibitors for Lung Cancer and Key Manufacturers
    13.2 Manufacturing Costs Percentage of EGFR Inhibitors for Lung Cancer
    13.3 EGFR Inhibitors for Lung Cancer Production Process
    13.4 EGFR Inhibitors for Lung Cancer Industrial Chain
14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 EGFR Inhibitors for Lung Cancer Typical Distributors
    14.3 EGFR Inhibitors for Lung Cancer Typical Customers
15 Research Findings and Conclusion
16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

FAQ's

It contains all the geographic trends, and market analysis for global market